FAB
NEUTRALFusion Antibodies to Host Investor Presentation
The biotechnology company is hosting an online investor presentation to discuss its recent trading update.
Fusion Antibodies
5.80GBX
-2.52%
Market Cap
6.24M
Volume
230.35k
26% of avg
P/E Ratio
-0.02
EPS (TTM)
-2.5
Beta
0.49
Day Range
5.60p - 6.03p
52 Week Range
2.80p5.80p12.00p
5.80p
Upcoming Events
FAB
NEUTRALFusion Antibodies Issues Shares to Non-Executive Directors
The biotechnology company has issued new shares to its non-executive directors as part of their compensation.
FAB
NEUTRALFusion Antibodies Director Increases Stake
The healthcare company's CEO has purchased additional shares, increasing his direct holding in the business.
FAB
NEUTRALFusion Antibodies Announces Holding Change
The healthcare company has announced a change in shareholding, with no further details provided.
FAB
GOODFusion Antibodies Reports 71% Revenue Growth in FY2025
The biotechnology company reported a 71% increase in revenues for the financial year, driven by growth in the Diagnostics and Veterinary sectors. The firm also secured non-dilutive funding through grants and a successful equity raise.
FAB
NEUTRALFusion Antibodies Secures Grant Funding for Antibody Development Project
The contract research organization has been awarded a grant to develop a novel antibody therapy, providing non-dilutive funding for the project.
FAB
NEUTRALFusion Antibodies Announces Director Dealings
The healthcare company has announced changes to its major shareholders.
FAB
NEUTRALFusion Antibodies Announces Change in Shareholding
The healthcare company has announced a change in its major shareholder, with Unicorn Asset Management Limited increasing its stake in the business.
FAB
NEUTRALFusion Antibodies Announces Director Dealings
The biotechnology company has announced changes to its major shareholders.
FAB
GOODFusion Antibodies Raises £1.17 Million to Boost Growth Initiatives
The biotechnology company has raised £1.17 million through a share placing to support its growth initiatives, including validating its proprietary antibody platform and expanding commercialization activities.